

# EXHIBIT

# A

**EXHIBIT A**

<b><u>Exhibit Number</u></b>	<b><u>Description of Document</u></b>
OST	An Amgen memorandum dated December 3, 1984, entitled "Summary of Erythropoietin Clinical Panel Meeting." The document addresses criteria for establishing Phase I clinical trials.
OTW	Amgen meeting minutes dated July 16, 1985 entitled "Washington State University/Northwest Kidney Foundation as a Potential site for the EPO Phase I study." The minutes discuss a meeting held to discuss Dr. Adamson's potential role in Phase I clinical trials.
OUN	An Amgen letter to the FDA dated January 9, 1986 where Amgen submitted its application for obtaining designation of its drug, EPO, as an Orphan drug.
OUV and Demonstrative SP-52	An Amgen memorandum dated April 7, 1986 entitled "U. Washington EPO Clinical Study." It summarizes an April 4, 1986 phone conversation with Dr. Joe Eschbach regarding his clinical studies of EPO. Demonstrative SP-52 is a text cull-out of this document.
OUY	A May 6, 1986 letter from Dr. John Adamson to the NIH reporting on his activities relating to Phase I clinical trials of EPO. Moreover, this is not even an Amgen document, but rather, a letter from a third party to the NIH.
OWA	An April 15, 1987 letter and minutes from a March 3, 1987 "Meeting on Erythropoietin and Chronic Renal Failure."
QDZ	Amgen proposed protocol for its r-HuEPO Phase I clinical studies and copies of informed consent forms to be utilized in the Phase I clinical study.
PYY	An Amgen document dated December 3, 1985, entitled "Recombinant Human Erythropoietin – Phase I Clinical Trial."
OVZ	An April 9, 1987 letter from Amgen to Dr. Joe Eschbach attaching a Clinical Trial Protocol and two Informed Consent addendums.
OTI	A March 25, 1985 letter sent from Amgen to Dr. Goldwasser discussing protocol for human studies with EPO.